Literature DB >> 27136276

Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

R Mani1,2, R Yan3, X Mo4, C-S Chen1,2,3, M A Phelps5, R Klisovic6, J C Byrd1,2,3,6, W C Kisseberth1,7, C A London1,2,7, N Muthusamy1,2,6.   

Abstract

OSU-2S is a FTY720 (Fingolimod) derivative that lacks immunosuppressive properties but exhibits strong anti-tumour activity in several haematological and solid tumour models. We have recently shown OSU-2S to mediate potent cytotoxicity in human mantle cell lymphoma cell lines and primary cells. We report here the pre-clinical activity of OSU-2S in spontaneous B-cell lymphoma of dogs which shares many characteristics of human lymphoma. OSU-2S mediated apoptosis in canine B-cell lines and primary B-cell lymphoma cells obtained from spontaneous lymphoma bearing dogs. OSU-2S induced reactive oxygen species (ROS) in canine lymphoma cells and inhibition of ROS partially rescued OSU-2S-mediated cell death. These studies provide a rational basis for the use of spontaneous lymphoma in pet dogs as a preclinical large animal model for the development of OSU-2S as small molecule for treating people and dogs with lymphoma.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell lymphoma; FTY720; OSU-2S; canine lymphoma; small molecule

Mesh:

Substances:

Year:  2016        PMID: 27136276      PMCID: PMC5093090          DOI: 10.1111/vco.12221

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  12 in total

1.  ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

Authors:  Rajeswaran Mani; Chi-Ling Chiang; Frank W Frissora; Ribai Yan; Xiaokui Mo; Sivasubramanian Baskar; Christoph Rader; Rebecca Klisovic; Mitch A Phelps; Ching-Shih Chen; Robert J Lee; John C Byrd; Robert Baiocchi; L James Lee; Natarajan Muthusamy
Journal:  Exp Hematol       Date:  2015-04-29       Impact factor: 3.084

Review 2.  Small molecule inhibitors in veterinary oncology practice.

Authors:  Cheryl A London
Journal:  Vet Clin North Am Small Anim Pract       Date:  2014-07-12       Impact factor: 2.093

Review 3.  Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications.

Authors:  Daisuke Ito; Aric M Frantz; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2014-02-24       Impact factor: 2.046

Review 4.  Spontaneously occurring tumors of companion animals as models for human cancer.

Authors:  D M Vail; E G MacEwen
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

5.  Canine lymphoma-associated antigens defined by murine monoclonal antibodies.

Authors:  Z Steplewski; K A Jeglum; C Rosales; N Weintraub
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 6.  Dog models of naturally occurring cancer.

Authors:  Jennie L Rowell; Donna O McCarthy; Carlos E Alvarez
Journal:  Trends Mol Med       Date:  2011-03-24       Impact factor: 11.951

7.  Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.

Authors:  V E Valli; P H Kass; M San Myint; F Scott
Journal:  Vet Pathol       Date:  2013-02-26       Impact factor: 2.221

8.  Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model.

Authors:  Barbara C Rütgen; Saskia Willenbrock; Nicola Reimann-Berg; Ingrid Walter; Andrea Fuchs-Baumgartinger; Siegfried Wagner; Boris Kovacic; Sabine E Essler; Ilse Schwendenwein; Ingo Nolte; Armin Saalmüller; Hugo Murua Escobar
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

9.  Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.

Authors:  Hany A Omar; Chih-Chien Chou; Lisa D Berman-Booty; Yihui Ma; Jui-Hsiang Hung; Dasheng Wang; Takayuki Kogure; Tushar Patel; Luigi Terracciano; Natarajan Muthusamy; John C Byrd; Samuel K Kulp; Ching-Shih Chen
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.298

10.  Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.

Authors:  R Mani; Y Mao; F W Frissora; C-L Chiang; J Wang; Y Zhao; Y Wu; B Yu; R Yan; X Mo; L Yu; J Flynn; J Jones; L Andritsos; S Baskar; C Rader; M A Phelps; C-S Chen; R J Lee; J C Byrd; L J Lee; N Muthusamy
Journal:  Leukemia       Date:  2014-06-20       Impact factor: 11.528

View more
  4 in total

1.  Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats.

Authors:  Zhiliang Xie; Min Chen; Swagata Goswami; Rajes Mani; Dasheng Wang; Samuel K Kulp; Chris C Coss; Larry J Schaaf; Fengyu Cui; John C Byrd; Ryan N Jennings; Karsten K Schober; Carrie Freed; Stephanie Lewis; Raphael Malbrue; Natarajan Muthusamy; Chad Bennett; William C Kisseberth; Mitch A Phelps
Journal:  AAPS J       Date:  2020-07-16       Impact factor: 4.009

Review 2.  Inhibitors of Ceramide- and Sphingosine-Metabolizing Enzymes as Sensitizers in Radiotherapy and Chemotherapy for Head and Neck Squamous Cell Carcinoma.

Authors:  Yoshiaki Yura; Atsushi Masui; Masakazu Hamada
Journal:  Cancers (Basel)       Date:  2020-07-26       Impact factor: 6.639

Review 3.  Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration.

Authors:  Andrew R Clark; Michael Ohlmeyer
Journal:  Pharmacol Ther       Date:  2019-06-01       Impact factor: 12.310

Review 4.  PP2A and Its Inhibitors in Helper T-Cell Differentiation and Autoimmunity.

Authors:  Mohd Moin Khan; Ubaid Ullah Kalim; Meraj H Khan; Riitta Lahesmaa
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.